Clinical trial
ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic…
NCT00141453 · Daiichi Sankyo Co., Ltd., Industry · Completed
Key facts
| NCT number | NCT00141453 |
|---|---|
| Title | ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial |
| Official title | CS-866DM Phase 3 Clinical Study: A Double-Blind Controlled Trial in Patients With Diabetic Nephropathy and Overt Proteinuria Secondary to Type 2 Diabetes Mellitus |
| Lead sponsor | Daiichi Sankyo Co., Ltd., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetic Nephropathy, Type 2 Diabetes Mellitus, Proteinuria |
| Intervention type | Drug |
| Interventions | olmesartan medoxomil, Placebo Tablets |
| Enrollment | 577 |
| Start date | Apr 1, 2003 |
| Primary completion | Aug 1, 2008 |
| Completion | Jan 1, 2009 |
| First posted | Sep 1, 2005 |
| Last update posted | May 10, 2011 |
| Countries | China, Japan |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: